BECTON DICKINSON & CO (BDX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-07

Key Insights

BD announced Q2 fiscal 2026 financial results (quarter ending March 31, 2026) on May 7, 2026, with the press release containing non-GAAP adjusted measures indicating management's focus on operational performance metrics.
The company has multiple near-term debt maturities including notes due June 4, 2026 (1.208%) and December 15, 2026 (1.900%), suggesting active debt management and refinancing activities in the near term.
This is a routine earnings announcement filing with no disclosure of material agreements, leadership changes, or significant operational disruptions, indicating normal business operations.

Want the newest filings?

This analysis covers the filing from 2026-05-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-29

BDX approved amendments to its bylaws on April 28, 2026, primarily updating the advance notice provision for contested elections, indicating routine corporate governance housekeeping rather than any material business changes.
The filing contains no material business developments, earnings announcements, executive changes, or strategic initiatives—this is a standard governance-focused 8-K with limited investor impact.
Multiple debt securities are listed as registered, with some notes due in mid-2026 (June and December), suggesting the company is managing near-term debt obligations during this filing period.

Filed: 2026-04-09

Becton, Dickinson and Company (BD) announced the retirement of Richard E. Byrd, Executive Vice President and President of the Interventional segment, effective in June 2026.
BD intends to name a successor to Mr. Byrd prior to his retirement date, indicating a smooth transition of leadership in the Interventional segment.
The company issued a press release related to Mr. Byrd's retirement, providing transparency to investors on this key organizational change.

Filed: 2026-04-02

Becton, Dickinson and Company (BD) has completed the spin-off of its Biosciences and Diagnostic Solutions business and combination with Waters Corporation, which will allow the company to focus on its core operations.
BD has provided recast historical financial information to assist investors in understanding the company's standalone operating results from continuing operations, excluding the spun-off business.
The company has disclosed several debt instruments, including notes due in 2026, 2031, 2032, and 2036, which could impact its capital structure and financing costs going forward.

Filed: 2026-02-25

Becton, Dickinson and Company announced the early tender results and pricing for its previously announced tender offers to purchase up to $2 billion in aggregate principal amount of various outstanding notes.
The company exercised its right to increase the offer subcap for the 4.685% Senior Notes and the aggregate offer cap, indicating potential demand for the tender offers.
Holders of the notes had to tender by the early tender date in order to receive the early tender payment, with the 3.794% Senior Notes being accepted on a prorated basis due to the aggregate offer cap being exceeded.

Filed: 2026-02-10

Becton Dickinson announced a tender offer to purchase up to $1.6 billion of its outstanding senior notes and debentures, indicating active balance sheet management.
The company is targeting a diverse set of fixed-income securities across different maturity dates, suggesting a strategic approach to liability optimization.
The tender offer covers 15 different note and debenture series, providing Becton Dickinson flexibility to manage its debt profile and potentially improve its capital structure.

Filed: 2026-02-09

Becton Dickinson is completing the spin-off of its Biosciences and Diagnostic Solutions business and combining it with Waters Corporation through a merger transaction.
The company has entered into several key agreements to govern the separation, including a Tax Matters Agreement, an Employee Matters Agreement, and an Intellectual Property Matters Agreement.
The spin-off and merger will allow Becton Dickinson to focus on its core medical device and pharmaceutical businesses, potentially unlocking value for shareholders.

Filed: 2026-02-09

Becton Dickinson reported its Q1 2026 financial results, which include non-GAAP financial measures that should be reviewed for additional context.
The company did not indicate it is an emerging growth company, suggesting it is a more mature, established organization.
Becton Dickinson has several debt securities trading on the New York Stock Exchange, including notes with maturity dates ranging from 2026 to 2036.

Other reports for BECTON DICKINSON & CO

Insider Trading Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.